From what 0 stock analysts predict, the share price for CytoMed Therapeutics Limited - Ordinary Shares (GDTC) might decrease by 100% in the next year. This is based on a 12-month average estimation for GDTC. Price targets go from $ to $. The majority of stock analysts believe GDTC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
CytoMed Therapeutics Limited - Ordinary Shares has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that CytoMed Therapeutics Limited - Ordinary Shares will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GDTC.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Bruce Jackson Benchmark | Speculative Buy | $5 | Reiterates | Oct 10, 2024 |
Bruce Jackson Benchmark | Speculative Buy | $5 | Reiterates | Jun 11, 2024 |
Bruce Jackson Benchmark | Speculative Buy | $5 | Reiterates | Dec 4, 2023 |
Bruce Jackson Benchmark | Speculative Buy | $5 | Initiates | Jul 21, 2023 |
When did it IPO
2023
Staff Count
0
Country
Singapore
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Wee Kiat Tan Ph.D.
Market Cap
$28.7M
In 2023, GDTC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GDTC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - The 74th Emerging Growth Conference is scheduled for August 21-22, 2024, as announced by EmergingGrowth.com, a small cap media portal.
Why It Matters - The Emerging Growth Conference showcases small-cap companies, influencing investor interest and potential stock movements in the sector, impacting market trends and investment strategies.
Summary - CytoMed has been granted another patent for its Allogeneic Induced Pluripotent Stem Cell-derived Hybrid Gamma Delta Natural Killer T cells technology.
Why It Matters - The patent strengthens CytoMed's competitive position, potentially enhancing its market value and attracting investment interest in the biotech sector focused on innovative cancer therapies.
Summary - CytoMed Therapeutics (NASDAQ:GDTC) has signed a research collaboration with Sengkang General Hospital to develop allogeneic cell-based immunotherapies for cancer treatment.
Why It Matters - The collaboration may enhance CytoMed's research capabilities and credibility, potentially leading to advancements in cancer treatment and impacting stock performance positively.
Summary - CytoMed Therapeutics (NASDAQ: GDTC) will launch a pilot program on June 1, 2024, to isolate and cryo-store PBMCs for loyal shareholders, supporting its strategy for cell-based therapies.
Why It Matters - CytoMed's pilot program to collect and store PBMCs could enhance its therapeutic offerings and shareholder loyalty, potentially increasing its market value and attractiveness to investors.
Summary - CytoMed Therapeutics has entered a research collaboration with Sengkang General Hospital to develop an injectable cartilage regeneration therapy using umbilical cord-derived stem cells, aiming for a Phase 1 trial in two years.
Why It Matters - CytoMed's collaboration with Sengkang General Hospital for a cartilage regeneration therapy could lead to significant advancements in regenerative medicine, potentially boosting stock value and market interest.
Summary - The Company has secured exclusive patent rights in Malaysia, the US, and China, potentially enhancing its market position and product offerings.
Why It Matters - Exclusive patent rights in Malaysia, the US, and China can enhance the company's competitive edge, potentially increase revenue streams, and attract investment interest.